| Title |
Medical combination therapies in Cushing’s disease
|
|---|---|
| Published in |
Pituitary, February 2015
|
| DOI | 10.1007/s11102-015-0641-x |
| Pubmed ID | |
| Authors |
Lucio Vilar, Luciana A. Naves, Márcio C. Machado, Marcello D. Bronstein |
| Abstract |
There has been growing interest on medical therapy for the management of Cushing's disease (CD), particularly in cases of persistent or recurrent hypercortisolism. Ketoconazole, an inhibitor of adrenal steroidogenesis, is the most widely used drug, whereas cabergoline and pasireotide are the most promising centrally acting agents. The main purpose of this review article is to highlight the options of medical treatment for CD, with a special emphasis on combination therapies, a topic that has only been addressed by a limited number of studies. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 29 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 21% |
| Student > Master | 5 | 17% |
| Researcher | 4 | 14% |
| Other | 2 | 7% |
| Student > Postgraduate | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 8 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 34% |
| Agricultural and Biological Sciences | 4 | 14% |
| Neuroscience | 4 | 14% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Psychology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 6 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2023.
All research outputs
#7,407,331
of 24,387,992 outputs
Outputs from Pituitary
#135
of 523 outputs
Outputs of similar age
#97,564
of 361,137 outputs
Outputs of similar age from Pituitary
#2
of 10 outputs
Altmetric has tracked 24,387,992 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 523 research outputs from this source. They receive a mean Attention Score of 3.6. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 8 of them.